Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 91

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Targeted Treatments for Cognitive and Neurodevelopmental Disorders in Tuberous Sclerosis Complex

de Vries, Petrus J. · 2010 · Neurotherapeutics

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nurt.2010.05.001

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 44

  1. de Vries, 2007, The tuberous sclerosis complex proteins–a GRIPP on cognition and neurodevelopment, Trends Mol Med, 13, 319, 10.1016/j.molmed.2007.06.003 · DOI · Paper page
  2. Jones, 1997, Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis, Hum Mol Genet, 6, 2155, 10.1093/hmg/6.12.2155 · DOI · Paper page
  3. Dabora, 2001, Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs, Am J Hum Genet, 68, 64, 10.1086/316951 · DOI · Paper page
  4. Roach, 1998, Tuberous sclerosis consensus conference: revised diagnostic criteria, J Child Neurol, 13, 624, 10.1177/088307389801301206 · DOI · Paper page
  5. Ridler, 2007, Neuroanatomical correlates of memory deficits in tuberous sclerosis complex, Cereb Cortex, 17, 261, 10.1093/cercor/bhj144 · DOI · Paper page
  6. Ridler, 2001, Widespread anatomical abnormalities of grey and white matter structure in tuberous sclerosis, Psychol Med, 31, 1437, 10.1017/S0033291701004561 · DOI
  7. Franz, 2009, Giant cell astrocytomas in tuberous sclerosis complex, Arch Dis Child, 94, 75
  8. Franz, 2006, Rapamycin causes regression of astrocytomas in tuberous sclerosis complex, Ann Neurol, 59, 490, 10.1002/ana.20784 · DOI · Paper page
  9. Prather, 2004, Behavioral and cognitive aspects of tuberous sclerosis complex, J Child Neurol, 19, 666, 10.1177/08830738040190090601 · DOI · Paper page
  10. Joinson, 2003, Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex, Psychol Med, 33, 335, 10.1017/S0033291702007092 · DOI · Paper page
  11. de Vries, 2007, The tuberous sclerosis complex, N Engl J Med, 356, 92, 10.1056/NEJMc062928 · DOI · Paper page
  12. Bolton, 2002, Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex, Brain, 125, 1247, 10.1093/brain/awf124 · DOI · Paper page
  13. de Vries, 2006, The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families, Eur Child Adolesc Psychiatry, 16, 16, 10.1007/s00787-006-0570-3 · DOI
  14. Lewis, 2004, Genotype and psychological phenotype in tuberous sclerosis, J Med Genet, 41, 203, 10.1136/jmg.2003.012757 · DOI
  15. Smalley, 1994, Phenotypic variation of tuberous sclerosis in a single extended kindred, J Med Genet, 31, 761, 10.1136/jmg.31.10.761 · DOI
  16. de Vries, 2009, Neuropsychological attention deficits in tuberous sclerosis complex (TSC), Am J Med Genet Part A, 149A, 387, 10.1002/ajmg.a.32690 · DOI
  17. McCartney, 2009, Lateralised spatial attentional bias and white matter tract connectivity in tuberous sclerosis complex (TSC), J Intell Disabil Res, 53, 836
  18. Sahakian, 1992, Computerized assessment in neuropsychiatry using CANTAB: discussion paper, J Royal Soc Med, 85, 399
  19. Kwiatkowski, 2005, Tuberous sclerosis: a GAP at the crossroads of multiple signalling pathways, Hum Mol Genet, 14, R251, 10.1093/hmg/ddi260 · DOI · Paper page
  20. Sampson, 2009, Therapeutic targeting of mTOR in tuberous sclerosis, Biochem Soc Trans, 37, 259, 10.1042/BST0370259 · DOI
  21. Jacinto, 2004, Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive, Nature Cell Biol, 6, 1122, 10.1038/ncb1183 · DOI · Paper page
  22. Serfontein, 2010, Evolution of the TSC1/TSC2-TOR signalling pathway, Sci Signal, 3, 49, 10.1126/scisignal.2000803 · DOI
  23. O'Callaghan, 2004, The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex, Arch Dis Child, 89, 530, 10.1136/adc.2003.026815 · DOI · Paper page
  24. Raznahan, 2007, Biological markers of intellectual disability in tuberous sclerosis, Psychol Med, 37, 1293, 10.1017/S0033291707000177 · DOI
  25. Jozwiak, 2009, New indications for antiepileptic drugs application in infants with tuberous sclerosis complex – prevention of epilepsy, Pharmacol Reports, 61, 580, 10.1016/S1734-1140(09)70104-5 · doi:10.1016/s1734-1140(09)70104-5
  26. Costa-Mattioli, 2009, Translational control of long-lasting synaptic plasticity and memory, Neuron, 61, 10, 10.1016/j.neuron.2008.10.055 · DOI · Paper page
  27. Goorden, 2007, Cognitive deficits in Tsc1+/− mice in the absence of cerebral lesions and seizures, Ann Neurol, 62, 648, 10.1002/ana.21317 · DOI · Paper page
  28. Nellist, 2005, Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex, Eur J Hum Genet, 13, 59, 10.1038/sj.ejhg.5201276 · DOI
  29. Persico, 2006, Searching for ways out of the autism maze: genetic, epigenetic and environmental clues, Trends Neurosci, 29, 349, 10.1016/j.tins.2006.05.010 · DOI · Paper page
  30. de Vries, 2009, Genetics and neuropsychiatric disorders: genome-wide, yet narrow, Nat Med, 15, 850, 10.1038/nm0809-850 · DOI
  31. Johannessen, 2005, The NF1 tumor suppressor critically regulates TSC2 and mTOR, Proc Natl Acad Sci USA, 102, 8573, 10.1073/pnas.0503224102 · DOI · Paper page
  32. Kenerson, 2005, Effects of rapamycin in the Eker rat model of tuberous sclerosis complex, Pediatr Res, 57, 67, 10.1203/01.PDR.0000147727.78571.07 · DOI · Paper page
  33. Lee, 2005, Efficacy of a rapamycin analog (CCI-779) and IFN-γ in tuberous sclerosis mouse models, Genes Chromosomes Cancer, 42, 213, 10.1002/gcc.20118 · DOI · Paper page
  34. Bissler, 2008, Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis, N Engl J Med, 358, 140, 10.1056/NEJMoa063564 · DOI · Paper page
  35. Davies, 2008, Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis, N Engl J Med, 358, 200, 10.1056/NEJMc072500 · DOI · Paper page
  36. Hofbauer, 2008, The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis, B J Dermatol, 159, 473, 10.1111/j.1365-2133.2008.08677.x · DOI
  37. Rauktys, 2008, Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model, BMC Dermatol, 8, 1, 10.1186/1471-5945-8-1 · DOI
  38. Krueger DA, Care MM, Agricola K, et al. Safety and efficacy of RAD001 (everolimus) for the treatment of subependymal giant cell astrocytoma in pediatric and adult patients with TSC. Presented at the TSC International Research Conference, University of Sussex; September 11–13, 2008; Brighton, UK.
  39. Zeng, 2008, Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex, Ann Neurol, 63, 444, 10.1002/ana.21331 · DOI · Paper page
  40. Meikle, 2008, Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signalling lead to improved survival and function, J Neurosci, 28, 5422, 10.1523/JNEUROSCI.0955-08.2008 · DOI · Paper page
  41. Krueger DA, Holland-Bouley K, Byers AW, et al. Effect of RAD001 (everolimus) on epilepsy and neurocognition in patients with TSC. Presented at the TSC International Research Conference, University of Sussex; September 11–13, 2008; Brighton, UK.
  42. Chen, 2005, PI3 kinase signalling is required for retrieval and extinction of contextual memory, Nat Neurosci, 8, 925, 10.1038/nn1482 · DOI · Paper page
  43. Dash, 2006, Spatial memory formation and memory-enhancing effect of glucose involves activation of the tuberous sclerosis complex-mammalian target of rapamycin pathway, J Neurosci, 26, 8048, 10.1523/JNEUROSCI.0671-06.2006 · DOI · Paper page
  44. de Vries PJ. The Neuroscience of TSC – are we at risk of getting lost between the bench and the bedside? Presented at the International TSC Research Conference: From DNA to Human Therapies; September 23–26, 2009; Chicago.

Cited by

See all 91

Metadata

Authors
de Vries, P. J.
Venue
Neurotherapeutics
Publisher
Elsevier BV
Published
2010-07
Volume
7
Issue
3
Pages
275-282
ISSN
1878-7479
Cited by
91
References
9
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.